Researchers from ETH Zurich, the Paul Scherrer Institute and Merck Millipore have developed a new PET tracer that binds to folic acid receptors, which builds up on the surface of many malignant cells. The agent could be used to collect data on the size and location of a tumor as well as the efficacy of chemotherapy, in particular a possible new class of drugs targeting the receptors. The scientists have assessed the tracer in mice with cervical tumors and are preparing to conduct a clinical trial on patients with ovarian, lung and intestinal cancers.

Full Story:

Related Summaries